Breast Cancer And Prostate Cancer
Published on Feb 17 2010, in the categories: Related pains
A study, the first one of this kind, conducted by a team of researchers of the Tropical Hygiene and Medicine school in London, on 1.9 million people from 31 countries, over 20 countries in Europe, USA, Canada, Australia, Brazil, Japan, Algeria and Cuba, showed that prostate cancer survival rates differ from one country to another. For example, in the USA is registered the best percentage, especially among Caucasian people.
Researchers compared the prostate cancer survival rates of 5 years between 1990 and 1994. Generally speaking, taking into consideration all cancer types, the best survival rates were registered in North America, followed by Australia, Japan and Occidental Europe. The least survival rates were registered in Algeria, where the researchers could only conduct the studies in the area of Setif.
As for breast cancer and prostate cancer, the best survival rates were registered in the United States of America. Japan has the largest percentage of survival rates for colorectal cancer for men and France- for colorectal cancer for women. The five year survival rate varies from 11.4% in colorectal cancer in men to 38.8% in breast cancer. In the United States of America, the numbers go from 56.4% in colorectal cancer in men to 91.1 % in prostate cancer. In France, the cancer survival rates go from 52.8% in rectal cancer to 79.8% for breast cancer.
The most significant cancer survival rates are in Occidental Europe, with less than 40% in prostate cancer in Denmark and 80% in Austria for the same type of cancer. In the United States of America, the cancer survival rate for Afro-Americans is worse than for Caucasians, with a difference of 7% for breast cancer and prostate cancer. Researchers believe these differences are caused by bad diagnosis and wrong treatment of some doctors.
The presence of three genetic defects favors prostate cancer survival rates, decreasing the cancer survival rate after the occurrence of this disease. Because at the time of the diagnosis doctors are not conscious of how the disease is going to progress (if it is a more hostile or a slower evolution), the treatment is one of the crucial aspects. A simple test could inform on the presence of the three genetic defects which would allow doctors to prescribe a more forceful treatment, which could eventually increase the cancer survival rate for the patient.
Statistics show that only 14% of patients who have the three genetic defects live for more than 11 years, compared to 85% of those who do not present all the three genetic defects. Unfortunately, there are just few patients who present all the three defective genes, according to an article available in the British Journal of Cancer. According to Professor Colin Cooper, some patients have such a slow evolution after being diagnosed with prostate cancer that they just simply do not require any kind of treatment. On the other hand some patients diagnosed with prostate cancer have such an aggressive evolution of this disease that the disease may become fatal shortly after the diagnosis.
Researchers compared the prostate cancer survival rates of 5 years between 1990 and 1994. Generally speaking, taking into consideration all cancer types, the best survival rates were registered in North America, followed by Australia, Japan and Occidental Europe. The least survival rates were registered in Algeria, where the researchers could only conduct the studies in the area of Setif.
As for breast cancer and prostate cancer, the best survival rates were registered in the United States of America. Japan has the largest percentage of survival rates for colorectal cancer for men and France- for colorectal cancer for women. The five year survival rate varies from 11.4% in colorectal cancer in men to 38.8% in breast cancer. In the United States of America, the numbers go from 56.4% in colorectal cancer in men to 91.1 % in prostate cancer. In France, the cancer survival rates go from 52.8% in rectal cancer to 79.8% for breast cancer.
The most significant cancer survival rates are in Occidental Europe, with less than 40% in prostate cancer in Denmark and 80% in Austria for the same type of cancer. In the United States of America, the cancer survival rate for Afro-Americans is worse than for Caucasians, with a difference of 7% for breast cancer and prostate cancer. Researchers believe these differences are caused by bad diagnosis and wrong treatment of some doctors.
The presence of three genetic defects favors prostate cancer survival rates, decreasing the cancer survival rate after the occurrence of this disease. Because at the time of the diagnosis doctors are not conscious of how the disease is going to progress (if it is a more hostile or a slower evolution), the treatment is one of the crucial aspects. A simple test could inform on the presence of the three genetic defects which would allow doctors to prescribe a more forceful treatment, which could eventually increase the cancer survival rate for the patient.
Statistics show that only 14% of patients who have the three genetic defects live for more than 11 years, compared to 85% of those who do not present all the three genetic defects. Unfortunately, there are just few patients who present all the three defective genes, according to an article available in the British Journal of Cancer. According to Professor Colin Cooper, some patients have such a slow evolution after being diagnosed with prostate cancer that they just simply do not require any kind of treatment. On the other hand some patients diagnosed with prostate cancer have such an aggressive evolution of this disease that the disease may become fatal shortly after the diagnosis.
If you liked this post, subscribe to our blog by filling your e-mail address below:
Want to add something? Post your comments